Opexa Therapeutics intends to price public offering of common shares

Aegis helps fund clinical studies, working capital, corporate purposes

By Devika Patel

Knoxville, Tenn., Sept. 15 – Opexa Therapeutics, Inc. will conduct a public offering of common stock with a 45-day greenshoe, according to an 8-K filed Monday with the Securities and Exchange Commission.

Aegis Capital Corp. is the sole bookrunning manager.

Proceeds will be used for clinical studies, preclinical and manufacturing activities and general corporate purposes, including working capital, research and development, business development and operational purposes.

The Woodlands, Texas-based Opexa develops and commercializes cell therapies to treat autoimmune diseases, such as multiple sclerosis, rheumatoid arthritis and diabetes.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.